Novartis loses Glivec patents case in India


The apex Indian court rejected Swiss based pharmaceutical company Novartis AG’s plea for retaining patent of its cancer drug Glivec. The development has the potential for better prospects for Indian pharmaceutical firms over well placed foreign brands.

A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln

According to analysts, the Supreme Court has set a legal precedent with this decision where it refuses to support patents on existing drugs sold in India. The decision is not a great sign for foreign firms in the middle of intellectual property disputes in India. This includes companies such as Pfizer Inc and Roche Holding AG.

Source: Reuters, WSJ

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s